Sage Rhino Capital LLC acquired a new stake in shares of GlaxoSmithKline plc (NYSE:GSK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,127 shares of the pharmaceutical company’s stock, valued at approximately $209,000.
Other institutional investors have also recently made changes to their positions in the company. Ellis Investment Partners LLC raised its position in shares of GlaxoSmithKline by 61.4% in the 1st quarter. Ellis Investment Partners LLC now owns 689 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 262 shares during the last quarter. CFM Wealth Partners LLC purchased a new position in GlaxoSmithKline in the 1st quarter worth approximately $27,000. Creative Financial Designs Inc. ADV purchased a new position in GlaxoSmithKline in the 2nd quarter worth approximately $31,000. Investment Research & Advisory Group Inc. lifted its holdings in GlaxoSmithKline by 227.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 864 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Manchester Financial Inc. lifted its holdings in GlaxoSmithKline by 382.4% in the 2nd quarter. Manchester Financial Inc. now owns 820 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares in the last quarter. 12.41% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Plc Glaxosmithkline purchased 361,111 shares of the stock in a transaction dated Tuesday, July 21st. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,499,998.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.
GlaxoSmithKline stock traded up $0.07 during mid-day trading on Friday, hitting $40.32. The company’s stock had a trading volume of 5,256,383 shares, compared to its average volume of 3,093,294. The company has a 50 day moving average of $40.90 and a 200-day moving average of $41.54. The stock has a market cap of $101.14 billion, a PE ratio of 11.96, a P/E/G ratio of 4.49 and a beta of 0.70. The company has a debt-to-equity ratio of 1.28, a quick ratio of 0.63 and a current ratio of 0.96. GlaxoSmithKline plc has a one year low of $31.43 and a one year high of $48.25.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, April 29th. The pharmaceutical company reported $0.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.18. The company had revenue of $11.64 billion for the quarter, compared to the consensus estimate of $10.95 billion. GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%. On average, equities research analysts forecast that GlaxoSmithKline plc will post 3.12 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be given a dividend of $0.4914 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.47. The ex-dividend date is Thursday, August 13th. This represents a $1.97 dividend on an annualized basis and a dividend yield of 4.88%. GlaxoSmithKline’s dividend payout ratio is presently 58.99%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.